Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous adipose-derived stromal vascular fraction (Assistance Publique-Hôpitaux de Marseille)
- Development stage
- Unknown
- Lead developer
- Assistance Publique - Hôpitaux de Marseille
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intralesional
01
Overview
Autologous adipose-derived stromal vascular fraction (ADSVF) is an investigational cell therapy developed by Assistance Publique Hopitaux De Marseille (AP-HM) for the treatment of recurrent bulbar urethral stenosis. The therapy involves the extraction of a patient's own adipose tissue via lipoaspiration, which is then processed to isolate the stromal vascular fraction (SVF). This fraction contains a heterogeneous population of cells, including mesenchymal stem cells (MSCs), endothelial progenitor cells, and pericytes, which possess regenerative, pro-angiogenic, and anti-fibrotic properties. In the SURF Phase 2 clinical trial, ADSVF is administered via intralesional injection into the fibrotic urethral lesion as an adjuvant to standard endoscopic urethrotomy. The therapeutic goal is to leverage the paracrine signaling and regenerative potential of the injected cells to modulate the wound-healing process, favor tissue regeneration over fibrosis, and ultimately reduce the high rate of stricture recurrence.
- Other names
- autologous ADSVFAdipose-Derived Stromal Vascular Fraction
Beyond the preview
Go deeper on autologous adipose-derived stromal vascular fraction (Assistance Publique-Hôpitaux de Marseille).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous adipose-derived stromal vascular fraction (Assistance Publique-Hôpitaux de Marseille).